Nanomedicines in Cancers Targeting and Therapy
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 46
Special Issue Editor
Interests: nanozyme; biomedical; oxidation stress; smart drug delivery; precisiontargeted drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanoparticles armed with antibodies, peptides or aptamers bind HER2, EGFR, PSMA, CD44 etc., homing in on tumor cells and cancer stem cells while bypassing healthy tissue. Prostate models couple diverse ligands to matching receptors for simultaneous imaging-and-therapy. Next-gen carriers add organelle-directing signals (mitochondria, nucleus) to amplify apoptosis or metabolic shutdown. Acid-, redox- or enzyme-cleavable linkers release drugs inside tumors, cutting systemic toxicity. Nanozyme, metal-organic framework, assemble drugs, hyaluronic micelles, boron-nitride sheets and lipid-polymer hybrids merge chemotherapy, chemodynamic therapy, photothermal/photodynamic agents and siRNA for orthogonal, resistance-evading attack. These molecular upgrades transform nanoparticles into programmable drugs that recognize cancer signatures, traffic to vital sub-cellular sites, and execute synchronized cytotoxic/immunostimulatory commands, defining the next horizon of oncology.
Dr. Wei Jiang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- tumor targeting
- cancer therapy
- drug delivery vehicle
- biomedical
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
